FACULTY
Shazia Nakhoda, MD
Assistant Professor
Department of Hematology/Oncology
Hematology-Lymphoma Program
Fox Chase Cancer Center
Philadelphia, PA
PROGRAM DESCRIPTION
This online program will provide clinicians who care for people with chronic lymphocytic leukemia and mantle cell leukemia with important updates about current and future management of the diseases. It includes two animations and case study discussions.
TARGET AUDIENCE
This program is targeted to academic and community hematologists and oncologists and other healthcare practitioners throughout the world who care for patients with B-cell malignancies.
LEARNING OBJECTIVES
Review the developing resistance and challenges to tolerability associated with Bruton’s tyrosine kinase (BTK) inhibition in patients with B-cell malignancies.
ACCREDITATION STATEMENT
Med Learning Group is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. This CME activity was planned and produced in accordance with the ACCME Essentials.
PHYSICIAN CREDIT DESIGNATION STATEMENT
Med Learning Group designates this enduring activity for a maximum of .25AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the virtually live activity.
DISCLOSURE POLICY STATEMENT
In accordance with the Accreditation Council for Continuing Medical Education ACCME Standards for Integrity and Independence in Accredited Continuing Education, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in an MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.
DISCLOSURE OF RELEVANT FINANCIAL RELATIONSHIP(S)
Shazia Nakhoda, MD | Consulting Fee | Bristol Myers Squibb, ADC Therapeutics, BTG/SERB |
Contracted Research | BTG/SERB |
All relevant financial relationships have been mitigated.
CME Content Review
The content of this activity was independently peer reviewed.
The reviewer of this activity has nothing to disclose.
CNE Content Review
The content of this activity was peer reviewed by a nurse reviewer.
The reviewer of this activity has nothing to disclose.
Staff, Planners and Managers
The staff, planners, and managers reported the following financial relationships or relationships to products or devices they have with ineligible companies related to the content of this CME/CE activity:
- Matthew Frese, General Manager of Med Learning Group has nothing to disclose.
- Christina Gallo, SVP, Educational Development for Med Learning Group has nothing to disclose.
- Lauren Welch, MA, VP, Outcomes and Accreditation for Med Learning Group has nothing to disclose.
- Deb Gordon, Medical Director for Med Learning Group, has nothing to disclose.
- Melissa A. Johnson, Senior Program Manager for Med Learning Group has nothing to disclose.
- Amanda Jenkins, Program Manager for Med Learning Group has nothing to disclose.
- Millena De Brito, Program Coordinator for Med Learning Group has nothing to disclose.
- Aimee Meissner, Accreditation and Outcomes Manager for Med Learning Group has nothing to disclose.
DISCLOSURE OF UNLABELED USE
Med Learning Group requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States. During the course of this lecture, the faculty may mention the use of medications for both FDA-approved and non-approved indications.
DISCLAIMER
Med Learning Group makes every effort to develop CME activities that are scientifically based. This activity is designed for educational purposes. Participants have a responsibility to utilize this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making expertise before applying any information, whether provided here or by others, for any professional use.
For CME questions, please contact Med Learning Group at [email protected]
Contact this CME provider at Med Learning Group for privacy and confidentiality policy statement information at https://www.medlearninggroup.com/privacy-policy/
AMERICANS WITH DISABILITIES ACT
Event staff will be glad to assist you with any special needs. Please contact Med Learning Group at [email protected]
PROGRAM DESCRIPTION
This online program will provide clinicians who care for people with chronic lymphocytic leukemia and mantle cell leukemia with important updates about current and future management of the diseases. It includes two animations and case study discussions.
TARGET AUDIENCE
This program is targeted to academic and community hematologists and oncologists and other healthcare practitioners throughout the world who care for patients with B-cell malignancies.
LEARNING OBJECTIVES
- Optimally sequence therapy in those patients who develop resistance to or are refractory to B-cell malignant treatment
ACCREDITATION STATEMENT
Med Learning Group is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. This CME activity was planned and produced in accordance with the ACCME Essentials.
PHYSICIAN CREDIT DESIGNATION STATEMENT
Med Learning Group designates this enduring activity for a maximum of .25 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the virtually live activity.
DISCLOSURE POLICY STATEMENT
In accordance with the Accreditation Council for Continuing Medical Education ACCME Standards for Integrity and Independence in Accredited Continuing Education, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in an MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.
DISCLOSURE OF RELEVANT FINANCIAL RELATIONSHIP(S)
Shazia Nakhoda, MD | Consulting Fee | Bristol Myers Squibb, ADC Therapeutics, BTG/SERB |
Contracted Research | BTG/SERB |
All relevant financial relationships have been mitigated.
CME Content Review
The content of this activity was independently peer reviewed.
The reviewer of this activity has nothing to disclose.
CNE Content Review
The content of this activity was peer reviewed by a nurse reviewer.
The reviewer of this activity has nothing to disclose.
Staff, Planners and Managers
The staff, planners, and managers reported the following financial relationships or relationships to products or devices they have with ineligible companies related to the content of this CME/CE activity:
- Matthew Frese, General Manager of Med Learning Group has nothing to disclose.
- Christina Gallo, SVP, Educational Development for Med Learning Group has nothing to disclose.
- Lauren Welch, MA, VP, Outcomes and Accreditation for Med Learning Group has nothing to disclose.
- Deb Gordon, Medical Director for Med Learning Group, has nothing to disclose.
- Melissa A. Johnson, Senior Program Manager for Med Learning Group has nothing to disclose.
- Amanda Jenkins, Program Manager for Med Learning Group has nothing to disclose.
- Millena De Brito, Program Coordinator for Med Learning Group has nothing to disclose.
- Aimee Meissner, Accreditation and Outcomes Manager for Med Learning Group has nothing to disclose.
DISCLOSURE OF UNLABELED USE
Med Learning Group requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States. During the course of this lecture, the faculty may mention the use of medications for both FDA-approved and non-approved indications.
DISCLAIMER
Med Learning Group makes every effort to develop CME activities that are scientifically based. This activity is designed for educational purposes. Participants have a responsibility to utilize this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making expertise before applying any information, whether provided here or by others, for any professional use.
For CME questions, please contact Med Learning Group at [email protected]
Contact this CME provider at Med Learning Group for privacy and confidentiality policy statement information at https://www.medlearninggroup.com/privacy-policy/
AMERICANS WITH DISABILITIES ACT
Event staff will be glad to assist you with any special needs. Please contact Med Learning Group at [email protected]
PROGRAM DESCRIPTION
This online program will provide clinicians who care for people with chronic lymphocytic leukemia and mantle cell leukemia with important updates about current and future management of the diseases. It includes two animations and case study discussions.
TARGET AUDIENCE
This program is targeted to academic and community hematologists and oncologists and other healthcare practitioners throughout the world who care for patients with B-cell malignancies.
LEARNING OBJECTIVES
- Evaluate the findings of late-stage BTK inhibitor clinical trials in individuals with relapsed/refractory B-cell malignancies
ACCREDITATION STATEMENT
Med Learning Group is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. This CME activity was planned and produced in accordance with the ACCME Essentials.
PHYSICIAN CREDIT DESIGNATION STATEMENT
Med Learning Group designates this enduring activity for a maximum of .25 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the virtually live activity.
DISCLOSURE POLICY STATEMENT
In accordance with the Accreditation Council for Continuing Medical Education ACCME Standards for Integrity and Independence in Accredited Continuing Education, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in an MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.
DISCLOSURE OF RELEVANT FINANCIAL RELATIONSHIP(S)
Shazia Nakhoda, MD | Consulting Fee | Bristol Myers Squibb, ADC Therapeutics, BTG/SERB |
Contracted Research | BTG/SERB |
All relevant financial relationships have been mitigated.
CME Content Review
The content of this activity was independently peer reviewed.
The reviewer of this activity has nothing to disclose.
CNE Content Review
The content of this activity was peer reviewed by a nurse reviewer.
The reviewer of this activity has nothing to disclose.
Staff, Planners and Managers
The staff, planners, and managers reported the following financial relationships or relationships to products or devices they have with ineligible companies related to the content of this CME/CE activity:
- Matthew Frese, General Manager of Med Learning Group has nothing to disclose.
- Christina Gallo, SVP, Educational Development for Med Learning Group has nothing to disclose.
- Lauren Welch, MA, VP, Outcomes and Accreditation for Med Learning Group has nothing to disclose.
- Deb Gordon, Medical Director for Med Learning Group, has nothing to disclose.
- Melissa A. Johnson, Senior Program Manager for Med Learning Group has nothing to disclose.
- Amanda Jenkins, Program Manager for Med Learning Group has nothing to disclose.
- Millena De Brito, Program Coordinator for Med Learning Group has nothing to disclose.
- Aimee Meissner, Accreditation and Outcomes Manager for Med Learning Group has nothing to disclose.
DISCLOSURE OF UNLABELED USE
Med Learning Group requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States. During the course of this lecture, the faculty may mention the use of medications for both FDA-approved and non-approved indications.
DISCLAIMER
Med Learning Group makes every effort to develop CME activities that are scientifically based. This activity is designed for educational purposes. Participants have a responsibility to utilize this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making expertise before applying any information, whether provided here or by others, for any professional use.
For CME questions, please contact Med Learning Group at [email protected]
Contact this CME provider at Med Learning Group for privacy and confidentiality policy statement information at https://www.medlearninggroup.com/privacy-policy/
AMERICANS WITH DISABILITIES ACT
Event staff will be glad to assist you with any special needs. Please contact Med Learning Group at [email protected]
PROGRAM DESCRIPTION
This online program will provide clinicians who care for people with chronic lymphocytic leukemia and mantle cell leukemia with important updates about current and future management of the diseases. It includes two animations and case study discussions.
TARGET AUDIENCE
This program is targeted to academic and community hematologists and oncologists and other healthcare practitioners throughout the world who care for patients with B-cell malignancies.
LEARNING OBJECTIVES
- Evaluate the findings of late-stage BTK inhibitor clinical trials in individuals with relapsed/refractory B-cell malignancies
ACCREDITATION STATEMENT
Med Learning Group is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. This CME activity was planned and produced in accordance with the ACCME Essentials.
PHYSICIAN CREDIT DESIGNATION STATEMENT
Med Learning Group designates this enduring activity for a maximum of .25 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the virtually live activity.
DISCLOSURE POLICY STATEMENT
In accordance with the Accreditation Council for Continuing Medical Education ACCME Standards for Integrity and Independence in Accredited Continuing Education, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in an MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.
DISCLOSURE OF RELEVANT FINANCIAL RELATIONSHIP(S)
Shazia Nakhoda, MD | Consulting Fee | Bristol Myers Squibb, ADC Therapeutics, BTG/SERB |
Contracted Research | BTG/SERB |
All relevant financial relationships have been mitigated.
CME Content Review
The content of this activity was independently peer reviewed.
The reviewer of this activity has nothing to disclose.
CNE Content Review
The content of this activity was peer reviewed by a nurse reviewer.
The reviewer of this activity has nothing to disclose.
Staff, Planners and Managers
The staff, planners, and managers reported the following financial relationships or relationships to products or devices they have with ineligible companies related to the content of this CME/CE activity:
- Matthew Frese, General Manager of Med Learning Group has nothing to disclose.
- Christina Gallo, SVP, Educational Development for Med Learning Group has nothing to disclose.
- Lauren Welch, MA, VP, Outcomes and Accreditation for Med Learning Group has nothing to disclose.
- Deb Gordon, Medical Director for Med Learning Group, has nothing to disclose.
- Melissa A. Johnson, Senior Program Manager for Med Learning Group has nothing to disclose.
- Amanda Jenkins, Program Manager for Med Learning Group has nothing to disclose.
- Millena De Brito, Program Coordinator for Med Learning Group has nothing to disclose.
- Aimee Meissner, Accreditation and Outcomes Manager for Med Learning Group has nothing to disclose.
DISCLOSURE OF UNLABELED USE
Med Learning Group requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States. During the course of this lecture, the faculty may mention the use of medications for both FDA-approved and non-approved indications.
DISCLAIMER
Med Learning Group makes every effort to develop CME activities that are scientifically based. This activity is designed for educational purposes. Participants have a responsibility to utilize this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making expertise before applying any information, whether provided here or by others, for any professional use.
For CME questions, please contact Med Learning Group at [email protected]
Contact this CME provider at Med Learning Group for privacy and confidentiality policy statement information at https://www.medlearninggroup.com/privacy-policy/
AMERICANS WITH DISABILITIES ACT
Event staff will be glad to assist you with any special needs. Please contact Med Learning Group at [email protected]
RELEASED DATE: May 30, 2023
EXPIRATION DATE: May 30, 2024
Copyright © 2023 Med Learning Group. All rights reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Med Learning Group is prohibited.